Laboratory Tests in the Diagnosis and Follow-Up of Pediatric Rheumatic Diseases: An Update

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 1, 2010, Pages 53-72

  Breda, Luciana ^a   Nozzi, Manuela ^a   De Sanctis, Sara ^a   Chiarelli, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Children; Disease; Laboratory; Rheumatic

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTISTREPTOLYSIN; AUTOANTIBODY; C REACTIVE PROTEIN; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CRYOGLOBULIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; FERRITIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LA ANTIBODY; MEVALONATE KINASE; NEOPTERIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PHOSPHOLIPID ANTIBODY; PROCALCITONIN; RO ANTIBODY; SERUM AMYLOID A; SMALL NUCLEAR RNA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; BIOLOGICAL MARKER;

AMYLOIDOSIS; ANAMNESIS; ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; BLOOD CYTOLOGY; CINCA SYNDROME; CYTOPENIA; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FAMILY HISTORY; FERRITIN BLOOD LEVEL; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; LABORATORY TEST; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PARTIAL THROMBOPLASTIN TIME; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; RHEUMATIC DISEASE; RHEUMATIC FEVER; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; STREPTOCOCCUS INFECTION; SYNOVIAL FLUID; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; UVEITIS; VEIN THROMBOSIS; BLOOD; CHILD; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; PROGNOSIS; RHEUMATIC DISEASES;

BIOLOGICAL MARKERS; CHILD; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PROGNOSIS; RHEUMATIC DISEASES; CLINICAL LABORATORY TECHNIQUES;

EID: 77955307730     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2008.12.001     Document Type: Review

References (195)

1. Lane S.K., Gravel J.W. Clinical utility of common serum rheumatologic tests. Am Fam Physician 2002, 65:1073-1080.
2. Wagner-Weiner L. Laboratory evaluation of children with rheumatic disease. Pediatr Ann 2002, 31:362-371.
3. Shearn M.A., Kang I.Y. Effect of age and sex on the erythrocyte sedimentation rate. J Rheumatol 1986, 13:297-298.
4. Kowalczyk J. Professor Edmund Biernacki (1866-1911) and the discovery of the erythrocyte sedimentation rate. S Afr Med J 2006, 96:40-41.
5. Sox H.C., Liang M.H. The erythrocyte sedimentation rate. Ann Intern Med 1986, 104:515-523.
6. Paulus H.E., Brahn E. Is erythrocyte sedimentation rate the preferable measure of the acute phase response in rheumatoid arthritis?. J Rheumatol 2004, 31:838-840.
7. Giannini E.H., Ruperto N., Ravelli A., Lovell D.J., Felson D.T., Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997, 40:1202-1209.
8. Ravelli A., Martini A. Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp Rheumatol 2003, 21(Suppl 31):S89-S93.
9. Tillett W.S., Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930, 52:561-571.
10. Volanakis J.E. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001, 38:189-197.
11. Kravitz M.S., Pitashny M., Shoenfeld Y. Protective molecules-C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (ApoA1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol 2005, 25:582-591.
12. Gershov D., Kim S., Brot N., Elkon K.B. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000, 192:1353-1364.
13. Du Clos T.W., Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 2004, 30:261-277.
14. Szalai A.J. C-reactive protein (CRP) and autoimmune disease: facts and conjectures. Clin Dev Immunol 2004, 11:221-226.
15. Moser K.L., Neas B.R., Salmon J.E., Yu H., Gray-McGuire C., Asundi N., et al. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci USA 1998, 95:14869-14874.
16. Shai R., Quismorio F.P., Li L., Kwon O.J., Morrison J., Wallace D.J., et al. Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Hum Mol Genet 1999, 8:639-644.
17. Pulliam P.N., Attia M.W., Cronan K.M. C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection. Pediatrics 2001, 108:1275-1279.
18. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997, 24:1477-1485.
19. Gwither M., Schwarz H., Howard A., Ansell B.M. C-reactive protein in juvenile chronic arthritis: an indicator of disease activity and possibly amyloidosis. Ann Rheum Dis 1982, 41:259-262.
20. Wu J.F., Yang Y.H., Wang L.C., Lee J.H., Shen E.Y., Chiang B.L. Comparative usefulnessof C-reactive protein and erythrocyte sedimentation rate in juvenile rheumatoid arthritis. Clin Exp Rheumatol 2007, 25:782-785.
21. Pepys M.B., Lanham J.G., De Beer F.C. C-reactive protein in SLE. Clin Rheum Dis 1982, 8:91-103.
22. Yeh E.T. CRP as a mediator of disease. Circulation 2004, 109(Suppl 1):II11-II14.
23. Tabuchi M., Inoue K., Usui-Kataoka H., Kobayashi K., Teramoto M., Takasugi K., et al. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res 2007, 48:768-781.
24. Griselli M., Herbert J., Hutchinson W.L., Taylor K.M., Sohail M., Krausz T., et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999, 190:1733-1739.
25. Scirè C.A., Caporali R., Perotti C., Montecucco C. Plasma procalcitonin in rheumatic diseases. Reumatismo 2003, 55:113-118.
26. Chalumeau M., Leroy S., Gendrel D., Bréart G., Moulin F., Dubos F. Procalcitonin bedside testing in the pediatric emergency department. Arch Pediatr 2007, 14:529-531.
27. Delèvaux I., André M., Colombier M., Albuisson E., Meylheuc F., Bègue R.J., et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes?. Ann Rheum Dis 2003, 62:337-340.
28. Reinhart K., Karzai W., Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med 2000, 26:1193-1200.
29. Arkader R., Troster E.J., Lopes M.R., Júnior R.R., Carcillo J.A., Leone C., et al. Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child 2006, 91:117-120.
30. Korczowski B., Kowalczyk J.R., Bijak M., Rusin J. Concentration of procalcitonin and C-reactive protein in serum and erythrocyte sedimentation rate in active autoimmune diseases in children. Pol Merkur Lekarski 2003, 15:155-157.
31. Fernández Lopez A., Luaces Cubells C., García García J.J., Fernández Pou J. Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker. Pediatr Infect Dis J 2003, 22:895-903. Spanish Society of Pediatric Emergencies.
32. Eberhard O.K., Haubitz M., Brunkhorst F.M., Kliem V., Koch K.M., Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997, 40:1250-1256.
33. Butbul-Aviel Y., Koren A., Halevy R., Sakran W. Procalcitonin as a diagnostic aid in osteomyelitis and septic arthritis. Pediatr Emerg Care 2005, 21:828-832.
34. Okada Y., Minakami H., Tomomasa T., Kato M., Inoue Y., Kozawa K., et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect 2004, 48:199-205.
35. Catalano-Pons C., André M.C., Chalumeau M., Guérin S., Gendrel D. Lack of value of procalcitonin for prediction of coronary aneurysms in Kawasaki disease. Pediatr Infect Dis J 2007, 26:179-180.
36. Means R.T., Krantz S.B. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992, 80:1639-1647.
37. Raj D.S. Role of inerleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum 2008, 11. [Epub ahead of print].
38. Rusten L.S., Jacobsen S.E. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood 1995, 85:989-996.
39. Means R.T., Krantz S.B. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 1993, 91:416-419.
40. Papadaki H.A., Kritikos H.D., Valatas V., Boumpas D.T., Eliopoulos G.D. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-α antibody therapy. Blood 2002, 100:474-482.
41. Cazzola M., Ponchio L., de Benedetti F., Ravelli A., Rosti V., Beguin Y., et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996, 87:4824-4830.
42. Means R.T., Krantz S.B. Inhibition of human erythroid colony-forming units by γ interferon can be corrected by recombinant human erthropoietin. Blood 1991, 78:2564-2567.
43. Schooley J.C., Kullgren B., Allison A.C. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anemias. Br J Haematol 1987, 67:11-17.
44. Tzioufas A.G., Kokori S.I., Petrovas C.I., Moutsopoulos H.M. Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythematosus: correlation with anemia. Arthritis Rheum 1997, 40:2212-2216.
45. Casadevall N., Dupuy E., Molho-Sabatier P., Tobelem G., Varet B., Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996, 334:630-633.
46. Vreugdenhil G., Baltus C.A., van Eijk H.G., Swaak A.J. Anemia of chronic disease: diagnostic significance of erythrocyte and serological parameters in iron deficient rheumatoid arthritis patients. Br J Rheumatol 1990, 29:105-110.
47. Song J.S., Park W., Bae S.K., Kim S.S., Lee Y.H., Choi J.W., et al. The usefulness of serum trasferrin receptor and ferritin for assessing anemia in rheumatoid arthritis: comparison with bone marrow iron study. Rheumatol Int 2001, 21:24-29.
48. Giannouli S., Voulgarelis M., Ziakas P.D., Tzioufas A.G. Anemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis 2006, 65:144-148.
49. Voulgarelis M., Kokori S.I., Ioannidis J.P., Tzioufas A.G., Kyriaki D., Moutsopoulos H.M. Anemia in systemic lupus erythematosus: aetiological profile and role of erythropoietin. Ann Rheum Dis 2000, 59:217-222.
50. Nossent J.C., Swaak A.J. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med 1991, 80:605-612.
51. Yu H.H., Wang L.C., Lee J.H., Lee C.C., Yang Y.H., Chiang B.L. Lymphopenia is associated with neuropsychiatric manifestations and disease activity in pediatric systemic lupus erythematosus patients. Rheumatology (Oxford) 2007, 46:1492-1494.
52. García Tello A., Villegas Martínez A., González Fernández A.F. Hematological abnormalities in patients with systemic lupus erythematosus. Ann Med Interne 2002, 19:539-543.
53. Perrin L.H., Lambert P.H., Miescher P.A. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J Clin Invest 1975, 56:165-176.
54. Baqi N., Moazami S., Singh A., Ahmad H., Balachandra S., Tejani A. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol 1996, 7:924-929.
55. Ting C.K., Hsieh K.H. A long term immunological study of childhood onset systemic lupus erythematosus. Ann Rheum Dis 1992, 51:45-51.
56. Truedsson L., Bengtsson A.A., Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007, 40:560-566.
57. Ratnoff W.D. Inherited deficiencies of complement in rheumatic diseases. Rheum Dis Clin North Am 1996, 22:75-94.
58. Boeckler P., Meyer A., Uring-Lambert B., Goetz J., Cribier B., Hauptmann G., et al. Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus?. A study of 25 patients. Clin Immunol 2006, 121:198-202.
59. Jaskowski T.D., Martins T.B., Litwin C.M., Hill H.R. Comparison of three different methods for measuring classical pathway complement activity. Clin Diagn Lab Immunol 1999, 6:137-139.
60. Theil E.C. Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. Ann Rev Biochem 1987, 56:289-315.
61. Zandman-Goddard G., Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev 2007, 6:457-463.
62. Malope B.I., MacPhail A.P., Alberts M., Hiss D.C. The ratio of serum transferrin receptor and serum ferritin in the diagnosis of iron status. Br J Haematol 2001, 115:84-89.
63. Pelkonen P., Swanljung K., Siimes M.A. Ferritinemia as an indicator of systemic disease activity in children with systemic juvenile rheumatoid arthritis. Acta Paediatr Scand 1986, 75:64-68.
64. Beyan E., Beyan C., Demirezer A., Ertuǧrul E., Uzuner A. The relationship between serum ferritin levels and disease activity in systemic lupus erythematosus. Scand J Rheumatol 2003, 32:225-228.
65. Allen C.E., Yu X., Kozinetz C.A., McClain K.L. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008, 50:1227-1235.
66. Janka G.E. Hemophagocytic syndromes. Blood Rev 2007, 21:245-253.
67. Garcia P.C., Longhi F., Branco R.C., Piva J.P., Lacks D., Tasker R.C. Ferritin levels in children with severe sepsis and septic shock. Acta Paediatr 2007, 96:1829-1831.
68. Marhaug G., Dowton S.B. Serum amyloid A: an acute phase apolipoprotein and precursor of AA amyloid. Baillieres Clin Rheumatol 1994, 8:553-573.
69. Uhlar C.M., Whitehead A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999, 265:501-523.
70. Koga T., Torigoshi T., Motokawa S., Miyashita T., Maeda Y., Nakamura M., et al. Serum amyloid A-induced IL-6 production by rheumatoid synoviocytes. FEBS Lett 2008, 582:579-585.
71. Ledue T.B., Weiner D.L., Sipe J.D., Poulin S.E., Collins M.F., Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998, 35:745-753.
72. Lachmann H.J., Goodman H.J., Gilbertson J.A., Gallimore J.R., Sabin C.A., Gillmore J.D., et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007, 356:2361-2371.
73. Pepys M.B. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Trans R Soc Lond B Biol Sci 2001, 356:203-211.
74. Packham J.C., Hall M.A. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002, 41:1428-1435.
75. Touitou I., Sarkisian T., Medlej-Hashim M., Tunca M., Livneh A., Cattan D., et al. Country as the primary risk factor for renal amyloidosis in familiar Mediterranean fever. Arthritis Rheum 2007, 56:1706-1712.
76. Mimouni A., Magal N., Stoffman N., Shohat T., Minasian A., Krasnov M., et al. Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics 2000, 105:E70.
77. Laxer R.M. Pharmacology and drug therapy. Textbook of Pediatric Rheumatology 2005, 76-141. Elsevier Saunders, Philadelphia, PA. 5th ed.
78. Petty R.E., Laxer R.M. Systemic Lupus Erythematosus. Textbook of Pediatric Rheumatology 2005, 342-391. Elsevier Saunders, Philadelphia, PA. 5th ed.
79. Feutren G., Mihatsch M.J. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992, 326:1654-1660.
80. Hoffmann A.L., Milman N., Byg K.E. Childhood sarcoidosis in Denmark 1979-1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr 2004, 93:30-36.
81. Belfer M.H., Stevens R.W. Sarcoidosis: a primary care review. Am Fam Physician 1998, 58:2041-2050. 2055-6.
82. Chesnutt A.N. Enigmas in sarcoidosis. West J Med 1995, 162:519-526.
83. Fauroux B., Clément A. Pediatric sarcoidosis. Paediatr Respir Rev 2005, 6:128-133.
84. DeRemee R.A. Sarcoidosis. Mayo Clin Proc 1985, 70:177-181.
85. Pachman L.M., Hayford J.R., Chung A., Daugherty C.A., Pallansch M.A., Fink C.W., et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998, 25:1198-1204.
86. Pachman L.M. Juvenile dermatomyositis (JDMS): new clues to diagnosis and pathogenesis. Clin Exp Rheumatol 1994, 12:69-73.
87. Suarez C.R., Andreeff M., Miller D.R. Serum LDH values in childhood acute leukemias and non-Hodgkin's lymphoma. Med Pediatr Oncol 1984, 12:89-92.
88. Sheldon J. Laboratory testing in autoimmune rheumatic diseases. Best Pract Res Clin Rheumatol 2004, 18:249-269.
89. Ferri C., Zignego A.L., Pileri S.A. Cryoglobulins. J Clin Pathol 2002, 55:4-13.
90. Shoenfeld Y., Twig G., Katz U., Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun 2008, 30:74-83.
91. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002, 14:548-552.
92. Hahn R.G., Knox L.M., Forman T.A. Evaluation of poststreptococcal illness. Am Fam Physician 2005, 71:1949-1954.
93. Group A streptococcal infections. The Red Book 2000, 526-536. American Academy of Pediatrics, Committee on Infectious Diseases, American Academy of Pediatrics, Elk Groove Village (IL).
94. Hilário M.O., Terreri M.T. Rheumatic fever and post-streptococcal arthritis. Best Pract Res Clin Rheumatol 2002, 16:481-494.
95. Stollerman G., Lewis A.J., Schultz I., Taranta A. Relationship of immune response to group A streptococci to the course of acute, chronic and recurrent rheumatic fever. Am J Med 1956, 20:163-169.
96. Roodpeyma S., Kamali Z., Zare R. Rheumatic fever: the relationship between clinical manifestations and laboratory tests. J Paediatr Child Health 2005, 41:97-100.
97. Dougados M. Synovial fluid cell analysis. Baillieres Clin Rheumatol 1996, 10:519-534.
98. Pal B., Nash J., Oppenheim B., Dean N., McFarlane L., Maxwell S. Is routine synovial fluid analysis necessary?. Lessons and recommendations from an audit. Rheumatol Int 1999, 18:181-182.
99. Offiah A.C. Acute osteomyelitis, septic arthritis and discitis: differences between neonates and older children. Eur J Radiol 2006, 60:221-232.
100. Neogi T., Gladman D.D., Ibanez D., Urowitz M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol 2006, 33:1785-1788.
101. Von Mühlen C.A., Tan E.M. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995, 24:323-358.
102. Malleson P.N., Sailer M., Mackinnon M.J. Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child 1997, 77:299-304.
103. Fenger M., Wiik A., Høier-Madsen M., Lykkegaard J.J., Rozenfeld T., Hansen M.S., et al. Detection of antinuclear antibodies by solid-phase immunoassays and immunoflorescence analysis. Clin Chem 2004, 50:2141-2147.
104. Perilloux B.C., Shetty A.K., Leiva L.E., Gedalia A. Antinuclear antibody (ANA) and ANA profile tests in children with autoimmune disorders: a retrospective study. Clin Rheumatol 2000, 19:200-203.
105. Cainelli F., Betterle C., Vento S. Antinuclear antibodies are common in an infectious environment but do not predict systemic lupus erythematosus. Ann Rheum Dis 2004, 63:1707-1708.
106. Deane P.M., Liard G., Siegel D.M., Baum J. The outcome of children referred to a pediatric rheumatology clinic with a positive antinuclear antibody test but without an autoimmune disease. Pediatrics 1995, 95:892-895.
107. McGhee J.L., Kickingbird L.M., Jarvis J.N. Clinical utility of antinuclear antibody tests in children. BMC Pediatr 2004, 4:13.
108. Woreta F., Thorne J.E., Jabs D.A., Kedhar S.R., Dunn J.P. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 2007, 143:647-655.
109. Ravelli A., Felici E., Magni-Manzoni S., Pistorio A., Novarini C., Bozzola E., et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum 2005, 52:826-832.
110. Hiraki L.T., Benseler S.M., Tyrrell P.N., Hebert D., Harvey E., Silverman E.D. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008, 152:550-556.
111. Campos L.M., Kiss M.H., Scheinberg M.A., Mangueira C.L., Silva C.A. Antinucleosome antibodies in patients with juvenile systemic lupus erythematosus. Lupus 2006, 15:496-500.
112. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha. Arthritis Rheum 2000, 43:2383-2390.
113. Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet 2002, 359:540-541.
114. ter Borg E.J., Horst G., Hummel E.J., Limburg P.C., Kallenberg C.G. Measurement of increases in anti-double stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long term, prospective study. Arthritis Rheum 1990, 33:634-643.
115. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000, 53:424-432.
116. Vargas M.T., Gustilo K., D'Andrea D.M., Kalluri R., Foster M.H., Madaio M.P. Structural features of nephritogenic lupus autoantibodies. Methods 1997, 11:62-69.
117. van Paassen P., Damoiseaux J., Tervaert J.W. Laboratory assessment in musculoskeletal disorders. Best Pract Clin Res Rheumatol 2003, 17:475-494.
118. Houghton K., Malleson P., Cabral D., Petty R., Tucker L. Primary Sjögren's syndrome in children and adolescents: are proposed diagnostic criteria applicable?. J Rheumatol 2005, 32:225-232.
119. Cimaz R., Casadei A., Rose C., Bartunkova J., Sediva A., Falcini F., et al. Primary Sjögren syndrome in the pediatric age: a multicentre survey. Eur J Pediatr 2003, 162:661-665.
120. Brucato A., Frassi M., Franceschini F., Cimaz R., Faden D., Pisoni M.P., et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001, 44:1832-1835.
121. Gordon P., Khamashta M.A., Rosenthal E., Simpson J.M., Sharland G., Brucato A., et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 2004, 31:2480-2487.
122. Horsfall A.C., Venables P.J., Taylor P.V., Maini R.N. Ro and La antigens and maternal anti-La idiotype on the surface of myocardial fibres in congenital heart block. J Autoimmun 1991, 4:165-176.
123. Gaudreau A., Amor B., Kahn M.F., Ryckewaert A., Sany J., Peltier A.P. Clinical significance of antibodies to soluble extractable nuclear antigens (anti-ENA). Ann Rheum Dis 1978, 37:321-327.
124. Martini G., Foeldvari I., Russo R., Cuttica R., Eberhard A., Ravelli A., et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum 2006, 54:3971-3978.
125. Hossny E., Hady H.A., Mabrouk R. Anti-centromere antibodies as a marker of Raynaud's phenomenon in pediatric rheumatologic diseases. Pediatr Allergy Immunol 2000, 11:250-255.
126. Kampolis C., Plastiras S., Vlachoyiannopoulos P., Moyssakis I., Tzelepis G. The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis. Scand J Rheumatol 2008, 37:278-283.
127. Bernstein R.M. Autoantibodies in myositis. Baillieres Clin Neurol 1993, 2:599-615.
128. Feldman B.M., Rider L.G., Reed A.M., Pachman L.M. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008, 371:2201-2212.
129. Targoff I.N., Mamyrova G., Trieu E.P., Perurena O., Koneru B., O'Hanlon T.P., et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006, 54:3682-3689.
130. Gunawardena H., Wedderburn L.R., North J., Betteridge Z., Dunphy J., Chinoy H., et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008, 47:324-328.
131. Iverson G.L. Are antibodies to ribosomal P proteins a clinically useful predictor of neuropsychiatric manifestations in patients with systemic lupus erythematosus?. Lupus 1996, 5:634-635.
132. Press J., Palayew K., Laxer R.M., Elkon K., Eddy A., Rakoff D., et al. Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum 1996, 39:671-676.
133. Hanly J.G. Neuropsychiatric lupus. Rheum Dis Clin North Am 2005, 31:273-298.
134. Wu J.F., Yang Y.H., Wang L.C., Lee J.H., Shen E.Y., Chiang B.L. Antinucleosome antibodies correlate with the disease severity in children with systemic lupus erythematosus. J Autoimmun 2007, 27:119-124.
135. Su Y., Jia R.L., Han L., Li Z.G. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol 2007, 122:115-120.
136. Cervera R., Viñas O., Ramos-Casals M., Font J., García-Carrasco M., Sisó A., et al. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis 2003, 62:431-434.
137. Boren E., Gershwin M.E. Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev 2004, 3:401-406.
138. Thewissen M., Somers V., Venken K., Linsen L., van Paassen P., Geusens P., et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin Immunol 2007, 123:209-218.
139. Eichenfield A.H., Athreya B.H., Doughty R.A., Cebul R.D. Utility of rheumatoid factor in the diagnosis of juvenile rheumatoid arthritis. Pediatrics 1986, 78:480-484.
140. Syed R.H., Gilliam B.E., Moore T.L. Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology. Curr Rheumatol Rep 2008, 10:156-163.
141. Ferucci E.D., Majka D.S., Parrish L.A., Moroldo M.B., Ryan M., Passo M., et al. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2005, 52:239-246.
142. Avčin T., Cimaz R., Falcini F., Zulian F., Martini G., Simonini G., et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002, 61:608-611.
143. Low J.M., Chauhan A.K., Kietz D.A., Daud U., Pepmueller P.H., Moore T.L. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol 2004, 31:1829-1833.
144. Brunner J.K., Sitzmann F.C. Anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Mod Rheumatol 2006, 16:372-375.
145. de Laat B., Mertens K., de Groot P.G. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanisms. Nat Clin Pract Rheumatol 2008, 4:192-199.
146. Uthman I.W., Gharavi A.E. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002, 31:256-263.
147. Schultz D.R. Antiphospholipid antibodies: basic immunology and assays. Semin Arthritis Rheum 1997, 26:724-739.
148. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999, 353:1348-1353.
149. Wahl D.G., Guillemin F., de Maistre E., Perret C., Lecompte T., Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus 1997, 6:467-473.
150. Male C., Foulon D., Hoogendoorn H., Vegh P., Silverman E., David M., et al. Predictive value of persistent versus transient antiphopholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005, 106:4152-4158.
151. Nojima J., Iwatani Y., Suehisa E., Kuratsune H., Kanakura Y. The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica 2006, 91:699-702.
152. Kamat A.V., D'Cruz D.P., Hunt B.J. Managing antiphospholipid antibodies and antiphospholipid syndrome in children. Haematologica 2006, 91:1674-1680.
153. Vaarala O., Palosuo T., Kleemola M., Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986, 41:8-15.
154. Sène D., Piette J.C., Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev 2008, 7:272-277.
155. Berkun Y., Padeh S., Barash J., Uziel Y., Harel L., Mukamel M., et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum 2006, 55:850-855.
156. Kurugöl Z., Vardar F., Özkinay F., Kavakli K., Özkinay C. Lupus anticoagulant and protein S deficiency in otherwise healthy children with acute varicella infection. Acta Paediatr 2000, 89:1186-1189.
157. Manco-Johnson M.J., Nuss R., Key N., Moertel C., Jacobson L., Meech S., et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr 1996, 128:319-323.
158. Frauenknecht K., Lackner K., von Landenberg P. Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection. Immunobiology 2005, 799-805.
159. Mizumoto H., Maihara T., Hiejima E., Shiota M., Hata A., Seto S., et al. Transient antiphospholipid antibodies associated with acute infections in children: a report of three cases and a review of the literature. Eur J Pediatr 2006, 165:484-488.
160. Conley C.L., Hartman R.C. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952, 31:621-622.
161. Pengo V., Ruffatti A. Laboratory diagnosis of antiphospholipid syndrome. Reumatismo 2007, 59:187-191.
162. Harris E.N., Boey M.L., Mackworth-Young C.G., Gharavi A.E., Patel B.M., Loizou S., et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983, 2:1211-1214.
163. Pierangeli S.S., Harris E.N. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta 2005, 357:17-33.
164. Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003, 101:1827-1832.
165. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
166. Davies D.J., Moran J.E., Niall J.F., Ryan G.B. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?. Br Med J 1982, 285:606.
167. Schultz D.R., Tozman E.C. Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations. Semin Arthritis Rheum 1995, 25:143-159.
168. McLaren J.S., Stimson R.H., McRorie E.R., Coia J.E., Luqmani R.A. The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. Q J Med 2001, 94:615-621.
169. Šedivá A., Kolářová I., Bartůková J. Antineutrophil cytoplasmic antibodies in children. Eur J Pediatr 1998, 157:987-991.
170. Bartůková J., Tesař V., Šedivá A. Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies. Clin Immunol 2003, 106:73-82.
171. Jennette J.C., Wilkman A.S., Falk R.J. Diagnostic predictive value of ANCA serology. Kidney Int 1998, 53:796-798.
172. Frosch M., Foell D. Wegener granulomatosis in childhood and adolescence. Eur J Pediatr 2004, 163:425-434.
173. Faure-Fontenla M.A., Rodriguez-Suarez R.S., Arias-Velasquez R., Garcia-Gonzalez J.E. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus in childhood. J Rheumatol 1999, 26:2480-2481.
174. Smith J.A., Märker-Hermann E., Colbert R.A. Pathogenesis of ankylosing spondylitis: current concepts. Best Pract Res Clin Rheumatol 2006, 20:571-591.
175. Cornélis F. Genetics and clinical practice in rheumatology. Joint Bone Spine 2003, 70:458-464.
176. Thomson W., Donn R. Juvenile idiopathic arthritis genetics-what's new?. What's next?. Arthritis Res 2002, 4:302-306.
177. Prahalad S. Genetics of juvenile idiopathic arthritis: an update. Curr Opin Rheumatol 2004, 16:588-594.
178. Glass D.N., Giannini E.H. Juvenile rheumatoid arthritis as a complex genetic trait. Arthritis Rheum 1999, 42:2261-2268.
179. Rosen P., Thompson S., Glass D. Non-HLA gene polymorphisms in juvenile rheumatoid arthritis. Clin Exp Rheumatol 2003, 21:650-656.
180. Thomson W., Barrett J.H., Donn R., Pepper L., Kennedy L.J., Ollier W.E., et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology 2002, 41:1183-1189.
181. Zeggini E., Packham J., Donn R., Wordsworth P., Hall A., Thomson W. Association of HLA-DRB1*13 with susceptibility to uveitis in juvenile idiopathic arthritis in two independent data sets. Rheumatology (Oxford) 2006, 45:972-974. BSPAR Study Group.
182. Stojanov S., Kastner D.L. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005, 17:586-599.
183. Gattorno M., Martini A. Inherited autoinflammatory syndromes: an expanding new group of chronic inflammatory diseases. Clin Exp Rheumatol 2005, 23:133-136.
184. Brydges S., Kastner D.L. The systemic autoinflammatory diseases: inborn errors of the, innate immune system. Curr Top Microbiol Immunol 2006, 305:127-160.
185. Pras E., Aksentijevich I., Gruberg L., Balow J.E., Prosen L., Dean M., et al. Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Engl J Med 1992, 326:1509-1513.
186. Gumucio D.L., Diaz A., Schaner P., Richards N., Babcock C., Schaller M., et al. Fire and ICE: the role of pyrin domain-containing proteins in inflammation and apoptosis. Clin Exp Rheumatol 2002, 20(Suppl 26):S45-S53.
187. Drenth J.P., van der Meer J.W. Hereditary periodic fever. N Engl J Med 2001, 345:1748-1757.
188. Majeed H.A., El-Khateeb M., El-Shanti H., Rabaiha Z.A., Tayeh M., Najib D. The spectrum of familial Mediterranean fever gene mutations in Arabs: report of a large series. Semin Arthritis Rheum 2005, 34:813-818.
189. Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet 2001, 9:473-483.
190. Drenth J.P., Cuisset L., Grateau G., Vasseur C., van de Velde-Visser S.D., de Jong J.G., et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999, 22:178-181.
191. Hoffman H.M., Patel D.D. Genomic-based therapy: targeting interleukin-1 for autoinflammatory diseases. Arthritis Rheum 2004, 50:345-349.
192. McDermott M.F., Aksentijevich I., Galon J., McDermott E.M., Ogunkolade B.W., Centola M., et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor. TNFR1, define a family of dominantly inherited autoinflammatory syndromes Cell 1999, 97:133-144.
193. Hull K.M., Drewe E., Aksentijevich I., Singh H.K., Wong K., McDermott E.M., et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002, 81:349-368.
194. Gattorno M., Sormani M.P., D'Osualdo A., Pelagatti M.A., Caroli F., Federici S., et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008, 58:1823-1832.
195. Ali M., Manolios N. Proteomics in rheumatology: a new direction for old diseases. Semin Arthritis Rheum 2005, 35:67-76.